DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS ⚠️ Small Study / Early Comparative Evidence
Mutant KRAS is central to PDAC biology, making vaccine interception an emerging area of investigation. This phase 1 study evaluated whether mKRAS-VAX could generate KRAS-specific T-cell responses in high-risk patients.
Clinical Considerations
- Ninety percent of vaccinated patients developed mutant KRAS-specific T-cell responses after the vaccine course.
- The study included 20 high-risk patients with familial or germline predisposition and pancreatic cyst findings.
- No vaccinated patients developed PDAC or high-risk lesions over 16.5 months median follow-up.
- Reported adverse events were grade 1-2, most often injection-site reactions, fatigue, chills, and flu-like symptoms.
Practice Applications
- Recognize this as early immunoprevention research, not established PDAC prevention.
- Interpret immune response data separately from long-term cancer prevention outcomes.
- Monitor larger studies for durability, lesion outcomes, and clinical event reduction.
- Avoid framing mKRAS-VAX as clinically protective based on phase 1 data.
